新型抗类风湿性关节炎药物sarilumab

Sarilumab: A new drug for treatment of rheumatoid arthritis

sarilumab是美国食品药品管理局(FDA)在2017年2月批准的首个直接靶向IL-6受体复合α亚基(IL-6Rα)的全人源单克隆Ig G抗体,该药在2016年已在欧盟上市。sarilumab可与IL-6Rα以高亲和力结合,抑制IL-6/IL-6Rα复合物的形成,进而中断细胞因子介导的炎症信号级联,用于治疗对其他类风湿药无效的成人中度至重度活动性类风湿关节炎,其治疗结果安全有效,并且无严重不良事件报道。概述sarilumab的药理作用、临床研究、不良反应等研究进展。

Sarilumab is the first full-human monoclonal Ig G antibodies that directly target Il-6 receptors combined with IL-6 Rα subunit approved by the Food and Drug Administration（FDA） in February 2017, it has appeared on the market in European Union. Sarilumab binds to IL-6 Rα receptor with extremely high affinity and inhibits the formation of IL-6/IL-6 Rα complex, and thus interrupts the inflammatory signaling cascade mediated by cytokines. Sarilumab can be used to treat adults with moderately to severely active rheumatoid arthritis（RA） that is ineffective for other rheumatoid drugs. The therapeutic outcome is safe and effective, and no serious adverse events were reported. This review summarizes the research progress on the pharmacodynamic properties, the clinical trials, and adverse events of sarilumab so as to provide an alternative therapeutic option for RA patients.